122 related articles for article (PubMed ID: 38401512)
1. Discovery of WS-384, a first-in-class dual LSD1 and DCN1-UBC12 protein-protein interaction inhibitor for the treatment of non-small cell lung cancer.
Li A; Ma T; Wang S; Guo Y; Song Q; Liu H; Yu B; Feng S
Biomed Pharmacother; 2024 Apr; 173():116240. PubMed ID: 38401512
[TBL] [Abstract][Full Text] [Related]
2. Development of Highly Potent, Selective, and Cellular Active Triazolo[1,5- a]pyrimidine-Based Inhibitors Targeting the DCN1-UBC12 Protein-Protein Interaction.
Wang S; Zhao L; Shi XJ; Ding L; Yang L; Wang ZZ; Shen D; Tang K; Li XJ; Mamun M; Li H; Yu B; Zheng YC; Wang S; Liu HM
J Med Chem; 2019 Mar; 62(5):2772-2797. PubMed ID: 30803229
[TBL] [Abstract][Full Text] [Related]
3. Discovery of the antitumor activities of a potent DCN1 inhibitor compound 383 targeting LSD1 in gastric cancer.
Song Z; Gao K; Asmamaw MD; Liu YJ; Zheng YC; Shi XJ; Liu HM
Eur J Pharmacol; 2022 Feb; 916():174725. PubMed ID: 34953802
[TBL] [Abstract][Full Text] [Related]
4. Targeting DCN1-UBC12 Protein-Protein Interaction for Regulation of Neddylation Pathway.
Zhou H; Lu J; Yang CY; Sun Y; Wang S
Adv Exp Med Biol; 2020; 1217():349-362. PubMed ID: 31898237
[TBL] [Abstract][Full Text] [Related]
5. Development of phenyltriazole thiol-based derivatives as highly potent inhibitors of DCN1-UBC12 interaction.
Zhou W; Xu C; Dong G; Qiao H; Yang J; Liu H; Ding L; Sun K; Zhao W
Eur J Med Chem; 2021 May; 217():113326. PubMed ID: 33756127
[TBL] [Abstract][Full Text] [Related]
6. A potent small-molecule inhibitor of the DCN1-UBC12 interaction that selectively blocks cullin 3 neddylation.
Zhou H; Lu J; Liu L; Bernard D; Yang CY; Fernandez-Salas E; Chinnaswamy K; Layton S; Stuckey J; Yu Q; Zhou W; Pan Z; Sun Y; Wang S
Nat Commun; 2017 Oct; 8(1):1150. PubMed ID: 29074978
[TBL] [Abstract][Full Text] [Related]
7. High-Affinity Peptidomimetic Inhibitors of the DCN1-UBC12 Protein-Protein Interaction.
Zhou H; Zhou W; Zhou B; Liu L; Chern TR; Chinnaswamy K; Lu J; Bernard D; Yang CY; Li S; Wang M; Stuckey J; Sun Y; Wang S
J Med Chem; 2018 Mar; 61(5):1934-1950. PubMed ID: 29438612
[TBL] [Abstract][Full Text] [Related]
8. Validation of NEDD8-conjugating enzyme UBC12 as a new therapeutic target in lung cancer.
Li L; Kang J; Zhang W; Cai L; Wang S; Liang Y; Jiang Y; Liu X; Zhang Y; Ruan H; Chen G; Wang M; Jia L
EBioMedicine; 2019 Jul; 45():81-91. PubMed ID: 31208947
[TBL] [Abstract][Full Text] [Related]
9. Targeting the DCN1-UBC12 protein-protein interaction: novel approaches and future directions.
Fang Y; Yu B; Liao G; Liu HM
Future Med Chem; 2019 Nov; 11(22):2869-2871. PubMed ID: 31668094
[No Abstract] [Full Text] [Related]
10. Discovery of Potent and Selective 2-(Benzylthio)pyrimidine-based DCN1-UBC12 Inhibitors for Anticardiac Fibrotic Effects.
He ZX; An Q; Wei B; Zhou WJ; Wei BF; Gong YP; Zhang X; Gao G; Dong GJ; Huo JL; Zhang XH; Yang FF; Liu HM; Ma LY; Zhao W
J Med Chem; 2022 Jan; 65(1):163-190. PubMed ID: 34939411
[TBL] [Abstract][Full Text] [Related]
11. Discovery of an Orally Bioavailable Inhibitor of Defective in Cullin Neddylation 1 (DCN1)-Mediated Cullin Neddylation.
Hammill JT; Bhasin D; Scott DC; Min J; Chen Y; Lu Y; Yang L; Kim HS; Connelly MC; Hammill C; Holbrook G; Jeffries C; Singh B; Schulman BA; Guy RK
J Med Chem; 2018 Apr; 61(7):2694-2706. PubMed ID: 29547693
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of HZX-960, a novel DCN1-UBC12 interaction inhibitor, as a potential antifibrotic compound for liver fibrosis.
Zhou W; Dong G; Gao G; He Z; Xu J; Aziz S; Ma L; Zhao W
Biochem Cell Biol; 2022 Aug; 100(4):309-324. PubMed ID: 35544948
[TBL] [Abstract][Full Text] [Related]
13. LSD1-mediated stabilization of SEPT6 protein activates the TGF-β1 pathway and regulates non-small-cell lung cancer metastasis.
Hong Y; Li X; Zhu J
Cancer Gene Ther; 2022 Feb; 29(2):189-201. PubMed ID: 33664458
[TBL] [Abstract][Full Text] [Related]
14. TdIF1-LSD1 Axis Regulates Epithelial-Mesenchymal Transition and Metastasis via Histone Demethylation of E-Cadherin Promoter in Lung Cancer.
Liu Q; Xiong J; Xu D; Hao N; Zhang Y; Sang Y; Wang Z; Zheng X; Min J; Diao H; Raphael J; Maleki Vareki S; Koropatnick J; Min W
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008676
[TBL] [Abstract][Full Text] [Related]
15. E3 ligase Trim35 inhibits LSD1 demethylase activity through K63-linked ubiquitination and enhances anti-tumor immunity in NSCLC.
Tang F; Lu C; He X; Lin W; Xie B; Gao X; Peng Y; Yang D; Sun L; Weng L
Cell Rep; 2023 Dec; 42(12):113477. PubMed ID: 37979167
[TBL] [Abstract][Full Text] [Related]
16. Potent 5-Cyano-6-phenyl-pyrimidin-Based Derivatives Targeting DCN1-UBE2M Interaction.
Zhou W; Ma L; Ding L; Guo Q; He Z; Yang J; Qiao H; Li L; Yang J; Yu S; Zhao L; Wang S; Liu HM; Suo Z; Zhao W
J Med Chem; 2019 Jun; 62(11):5382-5403. PubMed ID: 31157974
[TBL] [Abstract][Full Text] [Related]
17. Oncogene LSD1 is epigenetically suppressed by miR-137 overexpression in human non-small cell lung cancer.
Zhang X; Zhang X; Yu B; Hu R; Hao L
Biochimie; 2017 Jun; 137():12-19. PubMed ID: 28223039
[TBL] [Abstract][Full Text] [Related]
18. Targeting NOTCH activation in small cell lung cancer through LSD1 inhibition.
Augert A; Eastwood E; Ibrahim AH; Wu N; Grunblatt E; Basom R; Liggitt D; Eaton KD; Martins R; Poirier JT; Rudin CM; Milletti F; Cheng WY; Mack F; MacPherson D
Sci Signal; 2019 Feb; 12(567):. PubMed ID: 30723171
[TBL] [Abstract][Full Text] [Related]
19. Piperidinyl Ureas Chemically Control Defective in Cullin Neddylation 1 (DCN1)-Mediated Cullin Neddylation.
Hammill JT; Scott DC; Min J; Connelly MC; Holbrook G; Zhu F; Matheny A; Yang L; Singh B; Schulman BA; Guy RK
J Med Chem; 2018 Apr; 61(7):2680-2693. PubMed ID: 29547696
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of LSD1 induces ferroptosis through the ATF4-xCT pathway and shows enhanced anti-tumor effects with ferroptosis inducers in NSCLC.
Du L; Yang H; Ren Y; Ding Y; Xu Y; Zi X; Liu H; He P
Cell Death Dis; 2023 Nov; 14(11):716. PubMed ID: 37923740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
